Latest filing published 08 Jul 2021 for Acumen Pharmaceuticals, Inc..
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Sands Capital Ventures Discovery Fund III, L.P.: trading record in brief
All filings by Sands Capital Ventures Discovery Fund III, L.P. on record concern Acumen Pharmaceuticals, Inc. In total, 3 filings cover trades dated 6 July 2021.
The open-market record is one-sided, with 1 purchase worth €5.7M and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
Most recently, on 8 July 2021, the filings show an open-market purchase worth €5.7M in Acumen Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Sands Capital Ventures Discovery Fund III, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,124,729 sharesCommon StockSEC:0000899243-21-027891:0
1 of 1 declaration
